Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01071226 · ClinicalTrials.gov registry record · NA

Peripheral Blood Stem Cell Transplantation Using the CliniMACS Device

A NA study, sponsored by Medical College of Wisconsin.

Completed
Registry status
NA
Development phase
60
Enrollment target

NCT01071226 is a NA study that has completed, run by Medical College of Wisconsin. The registered enrollment target is 60 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01071226, a NA study, has completed, sponsored by Medical College of Wisconsin.

COMPLETED
Registry status
NA
Development phase
60 participants
Enrollment target

Study Summary

T cell depletion utilizing the CliniMACS device will allow more precise, specific and controlled graft engineering of peripheral blood stem cells from unrelated and partially matched related donors without an increase in relapse or graft rejection and grade III or IV acute graft versus host disease (GVHD).

Interventions

  • DEVICE CliniMACS (CD+3, CD+19 depletion)
  • DEVICE CliniMACS (CD 34+ positive selection)
  • OTHER HSCT

Trial Details

FieldValue
Enrollment Target 60 participants
Start Date 2008-05
Est. Completion 2020-04-28
Phase NA

Sponsor

Medical College of Wisconsin

447 total trials

What the Registry Record Tells You About NCT01071226

The ClinicalTrials.gov registry entry for NCT01071226 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medical College of Wisconsin, which has 447 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 3 interventions - of which CliniMACS (CD+3, CD+19 depletion) is the first listed.

NCT01071226 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT01071226 about?

NCT01071226 is a clinical study titled "Peripheral Blood Stem Cell Transplantation Using the CliniMACS Device". T cell depletion utilizing the CliniMACS device will allow more precise, specific and controlled graft engineering of peripheral blood stem cells from unrelated and partially matched related donors without an increase in relapse or graft rejection and grade III or IV acute graft versus host disease ...

What is the current status of trial NCT01071226?

This trial is currently completed. It is a NA study. The enrollment target is 60 participants. The study started on 2008-05. Estimated completion is 2020-04-28.

What interventions are being tested in trial NCT01071226?

The interventions under investigation include: CliniMACS (CD+3, CD+19 depletion) (DEVICE), CliniMACS (CD 34+ positive selection) (DEVICE), HSCT (OTHER).

Who is sponsoring clinical trial NCT01071226?

This trial is sponsored by Medical College of Wisconsin, which has 447 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.